PTH is a key regulator of calcium and phosphorous homeostasis in the kidneys, movement of calcium from the skeleton, and the production of the active form of vitamin D in the kidneys. With this award, Extend Biosciences will be developing EXT608, a long-acting D-VITylated PTH for the treatment of hypoparathyroidism.
News
Extend Biosciences Featured in the Innovation Zone at the BIO2015 International Convention
Extend Biosciences was one of 12 NSF awardee companies with treatment-related technologies that was featured in the Innovation Zone at the BIO International Convention 2015 in Philadelphia, PA. The company received complimentary passes to the Convention, and the technology was showcased at the company’s kiosk in the Innovation Zone with a poster and a pitch presentation by CEO Tarik Soliman.
Extend Biosciences and LabCentral Resident Companies Featured in Science Magazine Article
Extend Biosciences and LabCentral companies Vaxess, Ymir Genomics, Advirna and others are featured in an article in Science magazine as part of a special issue on entrepreneurship. The article is titled, “Got a Startup? Rent a Bench”.
Extend Biosciences Selected to Receive MLSC MAP Grant
Extend Biosciences has been awarded a Milestone Achievement Program (MAP) grant of $200,000 from the Massachusetts Life Sciences Center. The company was one of twelve early-stage life sciences companies that was selected for an award in this new program, which was designed to provide grant funding to execute critical, value-creating technical milestones to early-stage life sciences companies.
Extend Biosciences’ Founder Laura M. Hales, Ph.D. Selected to Speak on a Biotech Entrepreneur Panel
Founder Laura M. Hales, Ph.D. spoke on a panel of women entrepreneurs at the “From Bench to Bedside: An Evening With Biotech Entrepreneurs” event sponsored by Tufts Biomedical Business Club and the Boston Entrepreneurs and Advanced Degrees Meetup Group (B.E.A.D.). The panel also featured Dr. Bonnie Fendrock (Cofounder and CEO of Cyta Therapeutics), Dr. Kathryn Kosuda (Cofounder and VP of Research and Development of Vaxess Technologies), and Cinzia Metallo (Founder and Managing Director at Biomille Technologies). The lively and interactive panel was moderated by Dr. Paulina Hill of Polaris Ventures.
Extend Biosciences is Awarded a Phase II grant from the National Science Foundation
The NSF awarded a Phase II grant to Extend Biosciences’ PI Tarik M. Soliman, Ph.D. for a project titled “A platform technology that significantly improves drug delivery”.
Extend Biosciences’ Founder Laura M. Hales, Ph.D. Selected to Speak on the Plenary Panel at MALSI Day
Founder Laura M. Hales, Ph.D. was invited to speak on MALSI day’s plenary panel, “Startups that got funded in the last 18 months”. The panel also featured Kevin Bitterman (Polaris Ventures and CEO of Editas Medicine), Nancy Briefs (CEO of Infobionic), and Ashok Chander (CEO of Cellanyx Diagnostics). The 7th annual Massachusetts Life Sciences Innovation (MALSI) Day is the biggest day for life sciences startups and innovation in the Commonwealth of Massachusetts. This year’s theme was “Can you still be creative?”
The Department of Defense Awards Extend Biosciences a $1M Phase II Contract
Extend Biosciences has been awarded a Phase II contract to continue working on a program of interest to the military that expands the current capabilities of the company’s platform technology.
Extend Biosciences is Accepted into LabCentral
In March 2014, Extend Biosciences moved their operations from Cambridge Biolabs to LabCentral, the premier laboratory facility for biotech startups in the heart of Kendall Square, Cambridge. Extend Biosciences was accepted into the incubator after a competitive admissions process.
Extend Biosciences Receives a Grant from the NIAAA
Extend Biosciences was awarded a Phase I SBIR grant from the National Institute on Alcohol Abuse and Alcoholism to work on a program for alcoholic liver disease (ALD) in a collaboration with fellow LabCentral resident company Advirna as well as Duke University.